Compare Centrus Energy Corp (LEU) vs Tango Therapeutics Inc. (TNGX) Price & Performance

Centrus Energy (LEU) trades at $134.28, down 0.76% on the day, with technical indicators showing a bearish trend. The company maintains strong fundamentals with $448.70M revenue and $77.80M net income for 2025, though profitability declined in 2026. Recent multi-year HALEU supply contracts with Antares and Radiant highlight Centrus' strategic position in the nuclear fuel market as the only US-licensed HALEU producer.

The stock presents a compelling growth opportunity in nuclear energy infrastructure with 46% analyst buy ratings and $218.10 consensus price target, but faces execution risks amid high valuation multiples (P/E 71.05) and recent earnings volatility. Key risks include dependency on nuclear policy support and competitive pressures in uranium enrichment.

TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.

Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.